FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jörg Thomas Hartmann

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jörg Thomas Hartmann; S Heeger; Christian Kollmannsberger; Frank Mayer; Marcus Schittenhelm; I Cascorbi; Carsten Bokemeyer
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Christoph Käcker; Stefan Küffer; Alexander Marx; Gunhild Mechtersheimer; Katharina Mössinger; Ole Steen Nielsen; Christian Sauer; Ulrike Schneider; Jean-Yves Blay; Cyril Fisher; Christian Hallermann; Jörg Thomas Hartmann; Pancras Cornelis Wilhelmus Hogendoorn; Peter Hohenberger; Frederike Svehla; Philipp Ströbel
High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01.
Salah-Eddin Al-Batran; Hans-Michael Altmannsberger; Akin Atmaca; Jörg Thomas Hartmann; Ralf-Dieter Hofheinz; N Homann; Claudia Pauligk; H Schmalenberg; K Steinmetz; D Werner; R Wirtz; Elke Jäger
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jörg Thomas Hartmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jörg Thomas Hartmann; S Heeger; Christian Kollmannsberger; Frank Mayer; Marcus Schittenhelm; I Cascorbi; Carsten Bokemeyer
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Investigational new drugs 2013;31(3):661-8.
2013: Christoph Käcker; Stefan Küffer; Alexander Marx; Gunhild Mechtersheimer; Katharina Mössinger; Ole Steen Nielsen; Christian Sauer; Ulrike Schneider; Jean-Yves Blay; Cyril Fisher; Christian Hallermann; Jörg Thomas Hartmann; Pancras Cornelis Wilhelmus Hogendoorn; Peter Hohenberger; Frederike Svehla; Philipp Ströbel
High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01.
Genes, chromosomes & cancer 2013;52(1):93-8.
2012: Salah-Eddin Al-Batran; Hans-Michael Altmannsberger; Akin Atmaca; Jörg Thomas Hartmann; Ralf-Dieter Hofheinz; N Homann; Claudia Pauligk; H Schmalenberg; K Steinmetz; D Werner; R Wirtz; Elke Jäger
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(7):1699-705.
2011: Carsten Bokemeyer; I Bondarenko; Ilhan Celik; Filippo de Braud; Jörg Thomas Hartmann; M Schlichting; Gunter Schuch; A Zubel; P Koralewski
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(7):1535-46.
2011: K Potthoff; Ralf-Dieter Hofheinz; J C Hassel; M Volkenandt; Florian Lordick; Jörg Thomas Hartmann; Meinolf Karthaus; Hanno Riess; H P Lipp; A Hauschild; T Trarbach; A Wollenberg
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(3):524-35.
2010: Johannes Classen; Rainer Souchon; Thomas Hehr; Michael Hartmann; Jörg Thomas Hartmann; D D
Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis.
Journal of cancer research and clinical oncology 2010;136(2):227-32.
2010: Johanna Manner; Bernhard Radlwimmer; Peter Hohenberger; Katharina Mössinger; Stefan Küffer; Christian Sauer; Djeda Belharazem; Andreas Zettl; Jean-Michel Coindre; Christian Hallermann; Jörg Thomas Hartmann; Detlef Katenkamp; Kathrin Katenkamp; Patrick Schöffski; Raf Sciot; Agnieszka Wozniak; Peter Lichter; Alexander Marx; Philipp Ströbel
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema.
The American journal of pathology 2010;176(1):34-9.
2009: Eray Goekkurt; Salah-Eddin Al-Batran; Jörg Thomas Hartmann; Ulrike Mogck; Gunter Schuch; Michael Kramer; Elke Jaeger; Carsten Bokemeyer; Gerhard Ehninger; Jan Stoehlmacher
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(17):2863-73.
2009: Jörg Thomas Hartmann; Michael Haap; Hans-Georg Kopp; Hans-Peter Lipp
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
Current drug metabolism 2009;10(5):470-81.
2009: Friedemann Honecker; Hendrik Wermann; Frank Mayer; Ad J M Gillis; Hans Stoop; Ruud J L M van Gurp; Karin Oechsle; Ewout Steyerberg; Jörg Thomas Hartmann; Winand N M Dinjens; J Wolter Oosterhuis; Carsten Bokemeyer; Leendert H J Looijenga
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2129-36.
2009: Claudius Falch; Thomas Kratt; Stefan Beckert; Andreas Kirschniak; Derek Zieker; Ingmar Königsrainer; Stefan Löb; Jörg Thomas Hartmann; Alfred Königsrainer; Björn L.D.M. Brücher
Surgery of colorectal carcinoma in patients aged over 80.
Onkologie 2009;32(1-2):10-6.
2009: Jan Pintoffl; Ines Meisinger; Frank Mayer; Marius Horger; Claus von Weyhern; Lothar Kanz; Jörg Thomas Hartmann
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma.
Anti-cancer drugs 2009;20(1):73-4.
2008: Jörg Thomas Hartmann; Lothar Kanz
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Archives of dermatology 2008;144(11):1525-6.
2008: Salah-Eddin Al-Batran; Jörg Thomas Hartmann; R Hofheinz; N Homann; V Rethwisch; S Probst; Jan Stoehlmacher; M R Clemens; R Mahlberg; M Fritz; Gernot Seipelt; M Sievert; Claudia Pauligk; Akin Atmaca; Elke Jäger
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(11):1882-7.
2008: Ralf-Dieter Hofheinz; Ulrich Beyer; Salah-Eddin Al-Batran; Jörg Thomas Hartmann
Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.
Onkologie 2008;31(5):271-81.
2008: Jörg Thomas Hartmann; Jan Pintoffl; Hendrik Kröning; Carsten Bokemeyer; Martin Holtmann; Thomas Höhler
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Onkologie 2008;31(5):237-41.
2008: Salah-Eddin Al-Batran; Jörg Thomas Hartmann; Stephan Probst; Harald Schmalenberg; Stephan Hollerbach; Ralf Hofheinz; Volker Rethwisch; Gernot Seipelt; Nils Homann; Gerhard Wilhelm; Gunter Schuch; Jan Stoehlmacher; Hans Günter Derigs; Susanna Hegewisch-Becker; Johannes Grossmann; Claudia Pauligk; Akin Atmaca; Carsten Bokemeyer; Alexander Knuth; Elke Jäger
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1435-42.
2008: Carsten Bokemeyer; Karin Oechsle; Friedemann Honecker; Frank Mayer; Jörg Thomas Hartmann; C F Waller; I Böhlke; Christian Kollmannsberger
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):448-53.
2008: Karim Fizazi; J Oldenburg; Ariane Dunant; I Chen; Roberto Salvioni; Jörg Thomas Hartmann; M De Santis; G Daugaard; A Flechon; Ugo De Giorgi; S Tjulandin; Hans-J Schmoll; Jeannine Bouzy; Sophie D Fossa; Gaëlle Fromont
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):259-64.
2008: Hans-Georg Kopp; Shreyaskumar Patel; Björn L.D.M. Brücher; Jörg Thomas Hartmann
Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
American journal of clinical dermatology 2008;9(4):207-17.
2008: Axel S Merseburger; Mario W Kramer; Jörg Hennenlotter; Perikles Simon; Judith Knapp; Jörg Thomas Hartmann; Arnulf Stenzl; Jürgen Serth; Markus A Kuczyk
Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
The Prostate 2008;68(1):72-7.
2007: Jörg Thomas Hartmann; Thomas Gauler; Bernd Metzner; Arthur Gerl; Jochen Casper; Oliver Rick; Marius Horger; Jan Schleicher; Günter Derigs; Regine Mayer-Steinacker; Jörg Beyer; Markus A Kuczyk; Carsten Bokemeyer
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(36):5742-7.
2007: Sandra Mueller; Ulrike Hartmann; Frank Mayer; Stefan Balabanov; Jörg Thomas Hartmann; Tim H Brummendorf; Carsten Bokemeyer
Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Investigational new drugs 2007;25(6):519-24.
2007: K Krauss; Cornelia Bachmann; Jörg Thomas Hartmann; Katja Siegmann; Karl Sotlar; Diethelm Wallwiener; Jens Huober
Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole.
Anticancer research 2007;27(5B):3477-80.
2007: Michael Haap; Baptist Gallwitz; Claus Thamer; Karsten Müssig; Hans-Ulrich Häring; Lothar Kanz; Jörg Thomas Hartmann
Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.
Journal of endocrinological investigation 2007;30(8):688-92.
2007: Frank Mayer; Hermann Aebert; Maximilian Rudert; Alfred Königsrainer; Marius Horger; Lothar Kanz; D D; Gerhard Ziemer; Jörg Thomas Hartmann
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience.
The oncologist 2007;12(9):1134-42.
2007: Jörg Thomas Hartmann; Frank Mayer; Jan Schleicher; Marius Horger; Jens Huober; Ines Meisinger; Jan Pintoffl; Gabriele Käfer; Lothar Kanz; Viktor Grünwald
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
Cancer 2007;110(4):861-6.
2007: Hans-Georg Kopp; Marius Horger; Christoph Faul; Jörg Thomas Hartmann; Lothar Kanz; Peter Lang; Wichard Vogel
Granulocyte colony-stimulating factor induced pulmonary hemorrhage in a healthy stem cell donor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3174-5.
2007: Anja Lorch; Christian Kollmannsberger; Jörg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2778-84.
2007: Jörg Thomas Hartmann; Jan Pintoffl; Salah-Eddin Al-Batran; Detlef Quietzsch; Ines Meisinger; Marius Horger; Oliver Nehls; Carsten Bokemeyer; Alfred Königsrainer; Elke Jäger; Lothar Kanz
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
Onkologie 2007;30(5):235-40.
2007: Peter Reichardt; Ole Steen Nielsen; S Bauer; Jörg Thomas Hartmann; Patrick Schöffski; T B Christensen; Daniel Pink; S Daugaard; Sandrine Marreaud; Martine Van Glabbeke; J Y Blay
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2007;43(6):1017-22.
2007: Karin Oechsle; Friedemann Honecker; Christian Kollmannsberger; Oliver Rick; Victor Grünwald; Frank Mayer; Jörg Thomas Hartmann; Carsten Bokemeyer
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Anti-cancer drugs 2007;18(3):273-6.
2007: Jörg Thomas Hartmann
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Anti-cancer drugs 2007;18(3):245-54.
2007: Salah-Eddin Al-Batran; Anne Kerber; Akin Atmaca; Claudius Dechow; Ernst Reitsamer; Sebastian Schmidt; Yvonne Kolassa; Antje Neumann; Eckhart Weidmann; Jörg Thomas Hartmann; Elke Jäger
Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
Onkologie 2007;30(1-2):29-34.
2007: Salah-Eddin Al-Batran; Jörg Thomas Hartmann; Florian Heidel; Jan Stoehlmacher; Eva Wardelmann; Claudius Dechow; Markus Düx; Jacob Robert Izbicki; Thomas Kraus; Thomas Fischer; Elke Jäger
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2007;10(3):145-52.
2006: Karin Oechsle; Martin R Müller; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Onkologie 2006;29(12):557-61.
2006: Jörg Thomas Hartmann; Ines Meisinger; Stefan Kröber; Katja C Weisel; Karin Klingel; Lothar Kanz
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
Haematologica 2006;91(12 Suppl):ECR49.
2006: Hans-Georg Kopp; Lothar Kanz; Jörg Thomas Hartmann
Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide.
Anti-cancer drugs 2006;17(8):997-8.
2006: Sandra Mueller; Marcus Schittenhelm; Friedemann Honecker; Elke Malenke; Kirsten Lauber; Sebastian Wesselborg; Jörg Thomas Hartmann; Carsten Bokemeyer; Frank Mayer
Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
International journal of oncology 2006;29(2):471-9.
2006: Jörg Thomas Hartmann; Karin Oechsle; Jens Huober; Andreas Jakob; M Azemar; Marius Horger; Lothar Kanz; Carsten Bokemeyer
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Investigational new drugs 2006;24(3):249-53.
2006: Carmen Leichtle; Ulf Gunther Leichtle; V Gärtner; H Schimmel; Jörg Thomas Hartmann; Maximilian Rudert
Multiple skeletal metastases from a giant cell tumour of the distal fibula with fatal outcome.
The Journal of bone and joint surgery. British volume 2006;88(3):396-9.
2006: Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; D D; Jörg Thomas Hartmann
Advances in the treatment of testicular cancer.
Drugs 2006;66(5):641-59.
2006: Jörg Thomas Hartmann; Hans-Peter Lipp
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Drug safety : an international journal of medical toxicology and drug experience 2006;29(3):209-30.
2005: Jörg Thomas Hartmann; L Kanz
[Therapy for advanced colorectal carcinoma--new developments and standards].
Praxis 2005;94(49):1949-55.
2005: Michael Haap; Ina Kötter; Marius Horger; Claus Thamer; Manfred Wehrmann; Hans-Ulrich Häring; Lothar Kanz; Jörg Thomas Hartmann
Disseminated epitheloid hemangioendothelioma mimicking symptoms of systemic vasculitis.
Onkologie 2005;28(8-9):429-32.
2005: Jörg Thomas Hartmann; Oliver Rick; Karin Oechsle; Markus Kuczyk; Thomas Gauler; Patrick Schöffski; Jan Schleicher; Frank Mayer; Reinhard Teichmann; Lothar Kanz; Carsten Bokemeyer
Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors.
Annals of surgery 2005;242(2):260-6.
2005: Christian Kollmannsberger; W Budach; M Stahl; Norbert Schleucher; Thomas Hehr; Hansjochen Wilke; Jan Schleicher; Udo Vanhoefer; Ekkehard C Jehle; Karin Oechsle; Tanja Trarbach; I Boehlke; Lothar Kanz; Jörg Thomas Hartmann; Carsten Bokemeyer
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1326-33.
2005: Jörg Thomas Hartmann; Shreyaskumar Patel
New drug developments for patients with metastatic soft tissue sarcoma.
Current oncology reports 2005;7(4):300-6.
2005: Frank Mayer; Sandra Mueller; Elke Malenke; M Kuczyk; Jörg Thomas Hartmann; Carsten Bokemeyer
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Investigational new drugs 2005;23(3):205-11.
2005: Jan Wierecky; Christian Kollmannsberger; I Boehlke; Markus Kuczyk; Jan Schleicher; Norbert Schleucher; Bernd Metzner; Lothar Kanz; Jörg Thomas Hartmann; Carsten Bokemeyer
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Journal of cancer research and clinical oncology 2005;131(4):255-60.
2005: H R Salih; Jörg Thomas Hartmann
[Neuro-endocrine tumors of the gastrointestinal tract: epidemiology, classification, prognosis, diagnosis and therapeutic modalities].
Praxis 2005;94(8):291-302.
2005: H P Lipp; Jörg Thomas Hartmann
[Platinum compounds: metabolism, toxicity and supportive strategies].
Praxis 2005;94(6):187-98.
2005: Markus Kuczyk; Gerd Wegener; Axel S Merseburger; Aristotelis G Anastasiadis; Stefan Machtens; Andreas Zumbrägel; Jörg Thomas Hartmann; Carsten Bokemeyer; Udo Jonas; Arnulf Stenzl
Impact of tumor size on the long-term survival of patients with early stage renal cell cancer.
World journal of urology 2005;23(1):50-4.
2005: Jörg Thomas Hartmann; Shreyaskumar Patel
Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
Drugs 2005;65(2):167-78.
2004: Oliver Rick; Carsten Bokemeyer; Stefan Weinknecht; J Schirren; Tobias Pottek; Jörg Thomas Hartmann; T Braun; B Rachud; Lothar Weissbach; Michael Hartmann; Wolfgang Siegert; Jörg Beyer
Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3713-9.
2004: Ralf-Dieter Hofheinz; Jörg Thomas Hartmann; Andreas Willer; Karin Oechsle; Gernot Hartung; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Carsten Bokemeyer; Rüdiger Hehlmann; Andreas Hochhaus
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
British journal of cancer 2004;91(5):834-8.
2004: Carsten Bokemeyer; Christian Kollmannsberger; Sally P Stenning; Jörg Thomas Hartmann; Alan Horwich; C Clemm; Arthur Gerl; Christoph Meisner; C-P Rückerl; Hans-J Schmoll; Lothar Kanz; T Oliver
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.
British journal of cancer 2004;91(4):683-7.
2004: Hans-Georg Kopp; Lothar Kanz; Jörg Thomas Hartmann
Hypersensitivity pneumonitis associated with the use of trofosfamide.
Anti-cancer drugs 2004;15(6):603-4.
2004: Jörg Thomas Hartmann; Karin Oechsle; Elke Jäger; Hans-Edgar Reis; Cornelie Haag; Norbert Niederle; Hans-Joachim Wilke; Karl-Heinz Pflüger; Salah Al Batran; Thomas Büchele; Ralf-Dieter Hofheinz; Lothar Kanz; Carsten Bokemeyer
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Anti-cancer drugs 2004;15(5):473-7.
2004: Anna C Pfannenberg; Karin Oechsle; Carsten Bokemeyer; Christian Kollmannsberger; Bernhard M Dohmen; Roland Bares; Jörg Thomas Hartmann; Reinhard Vonthein; Claus D Claussen
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
World journal of urology 2004;22(2):132-9.
2004: Ralf-Dieter Hofheinz; Andreas Willer; Andreas Weisser; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Jörg Thomas Hartmann; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
British journal of cancer 2004;90(10):1893-7.
2004: Markus A Kuczyk; Carsten Bokemeyer; Christian Kollmannsberger; Stefan Corvin; Aristotelis G Anastasiadis; Stefan Machtens; Axel S Merseburger; Gerd Wegener; A Stenze; Jörg Thomas Hartmann; Udo Jonas
Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience.
World journal of urology 2004;22(1):55-9.
2004: Oliver Rick; Christian Kollmannsberger; Jörg Thomas Hartmann; T Braun; Wolfgang Siegert; Carsten Bokemeyer; Jörg Beyer
The role of high-dose chemotherapy in relapsed germ cell tumors.
World journal of urology 2004;22(1):25-32.
2004: Christian Kollmannsberger; Jörg Beyer; R Liersch; P Schoeffski; Bernd Metzner; Jörg Thomas Hartmann; Oliver Rick; K Stengele; K Hohloch; C Spott; Lothar Kanz; Carsten Bokemeyer
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):108-14.
2003: Jörg Thomas Hartmann; Karin Oechsle; Detlef Quietzsch; Axel Wein; Ralf-Dieter Hofheinz; Friedemann Honecker; O Nehls; Claus-Henning Köhne; G Käfer; Lothar Kanz; Carsten Bokemeyer
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
British journal of cancer 2003;89(11):2051-6.
2003: Hans-J Schmoll; Christian Kollmannsberger; Bernd Metzner; Jörg Thomas Hartmann; Norbert Schleucher; Patrick Schöffski; Jan Schleicher; Oliver Rick; Jörg Beyer; Dieter K Hossfeld; Lothar Kanz; Wolfgang E Berdel; Reinhard Andreesen; Carsten Bokemeyer
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4083-91.
2003: Peter Reichardt; Karin Oechsle; Daniel Pink; Carsten Bokemeyer; F Schneller; Rolf Issels; Lothar Kanz; Jörg Thomas Hartmann
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma.
Investigational new drugs 2003;21(4):481-6.
2003: Carsten Bokemeyer; Norbert Schleucher; Bernd Metzner; M Thomas; Oliver Rick; Hans-J Schmoll; Christian Kollmannsberger; I Boehlke; Lothar Kanz; Jörg Thomas Hartmann
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
British journal of cancer 2003;89(1):29-35.
2003: Jörg Thomas Hartmann; Hans-Peter Lipp
Toxicity of platinum compounds.
Expert opinion on pharmacotherapy 2003;4(6):889-901.
2003: Christian Kollmannsberger; Norbert Schleucher; Oliver Rick; Bernd Metzner; Jörg Thomas Hartmann; Patrick Schöffski; Jörg Beyer; Jochen Casper; M Sosada; Hans-J Schmoll; I Böhlke; Christoph Meisner; Lothar Kanz; Carsten Bokemeyer
Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.
European journal of cancer (Oxford, England : 1990) 2003;39(6):775-82.
2003: Jörg Thomas Hartmann; Karin Oechsle; Frank Mayer; Lothar Kanz; Carsten Bokemeyer
Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas.
Anticancer research 2003;23(2C):1899-901.
2003: Carsten Bokemeyer; Jörg Thomas Hartmann; Sophie D Fossa; Jean Pierre Droz; Hans-J Schmol; Alan Horwich; Arthur Gerl; Jörg Beyer; Jörg Pont; Lothar Kanz; Craig Nichols; Lawrence Einhorn
Extragonadal germ cell tumors: relation to testicular neoplasia and management options.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2003;111(1):49-59; discussion 59-63.
2002: Carsten Bokemeyer; Karin Oechsle; Jörg Thomas Hartmann; Patrick Schöffski; Norbert Schleucher; Bernd Metzner; Jan Schleicher; Lothar Kanz
Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer.
British journal of cancer 2002;87(10):1066-71.
2002: Jörg Thomas Hartmann; Craig Nichols; Jean Pierre Droz; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Lothar Kanz; Lawrence Einhorn; Carsten Bokemeyer
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1017-28.
2002: Friedemann Honecker; Christian Kollmannsberger; Detlef Quietzsch; Caroline Haag; M Schroeder; C Spott; Jörg Thomas Hartmann; W Baronius; V Hempel; Lothar Kanz; Carsten Bokemeyer
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Anti-cancer drugs 2002;13(5):497-503.
2002: Frank Mayer; Jörg Thomas Hartmann; Joachim von Pawel; J Beck; M Schroeder; I Boehlke; Lothar Kanz; Carsten Bokemeyer
A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):755-9.
2002: Carsten Bokemeyer; Craig Nichols; Jean Pierre Droz; Hans-J Schmoll; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Lothar Kanz; Lawrence Einhorn; Jörg Thomas Hartmann
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1864-73.
2002: Jörg Thomas Hartmann
Long-term effects of platin and anthracycline derivatives and possible prevention strategies.
Frontiers of radiation therapy and oncology 2002;37():92-100.
2001: Jörg Thomas Hartmann; Sophie D Fossa; Craig Nichols; Jean Pierre Droz; Alan Horwich; Arthur Gerl; Jörg Beyer; Jörg Pont; Karim Fizazi; H Hecker; Lothar Kanz; Lawrence Einhorn; Carsten Bokemeyer
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors.
Journal of the National Cancer Institute 2001;93(22):1733-8.
2001: Karim Fizazi; S Tjulandin; Roberto Salvioni; Josep Ramón Germà-Lluch; Jeannine Bouzy; D Ragan; Carsten Bokemeyer; Arthur Gerl; Aude Fléchon; J S de Bono; Sally P Stenning; Alan Horwich; Jörg Pont; P Albers; Ugo De Giorgi; mark bower; A Bulanov; Giorgio Pizzocaro; Jorge Aparicio; Craig Nichols; Christine Théodore; Jörg Thomas Hartmann; Hans-J Schmoll; S B Kaye; Stéphane Culine; Jean Pierre Droz; Cédric Mahé
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2647-57.
2001: Carsten Bokemeyer; Jean Pierre Droz; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Hans-J Schmoll; Lothar Kanz; Lawrence Einhorn; Craig Nichols; Jörg Thomas Hartmann
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
Cancer 2001;91(7):1394-401.
2001: Jörg Thomas Hartmann; Lawrence Einhorn; Craig Nichols; Jean Pierre Droz; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Hans-J Schmoll; Lothar Kanz; Carsten Bokemeyer
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1641-8.
2001: Jörg Thomas Hartmann; A von Vangerow; Lüder M Fels; Stefan Knop; Hilmar Stolte; Lothar Kanz; Carsten Bokemeyer
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
British journal of cancer 2001;84(3):313-20.
2001: Oliver Rick; Carsten Bokemeyer; Jörg Beyer; Jörg Thomas Hartmann; Nimrod Schwella; Dorothea Kingreen; S Neureither; Bernd Metzner; Jochen Casper; Hannes Wandt; F Hartmann; Hans-J Schmoll; Günter Derigs; Arthur Gerl; Wolfgang E Berdel; Lothar Kanz; Wolfgang Siegert
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):81-8.
2000: Carsten Bokemeyer; Jörg Thomas Hartmann; Frank Mayer; I Böhlke; Lothar Kanz; Joachim von Pawel; Günter Derigs; M Schröder
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):63-7.
2000: Jörg Thomas Hartmann; Lüder M Fels; A Franzke; Stefan Knop; M Renn; B Maess; P Panagiotou; H Lampe; Lothar Kanz; Hilmar Stolte; Carsten Bokemeyer
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Anticancer research 2000;20(5C):3767-73.
2000: Jörg Thomas Hartmann; Lüder M Fels; Stefan Knop; H Stolt; Lothar Kanz; Carsten Bokemeyer
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Investigational new drugs 2000;18(3):281-9.
2000: Christian Kollmannsberger; Detlef Quietzsch; Caroline Haag; T Lingenfelser; M Schroeder; Jörg Thomas Hartmann; W Baronius; V Hempel; Michael Clemens; Lothar Kanz; Carsten Bokemeyer
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
British journal of cancer 2000;83(4):458-62.
2000: Jörg Thomas Hartmann; Craig Nichols; Jean Pierre Droz; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Lawrence Einhorn; Lothar Kanz; Carsten Bokemeyer
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors.
Cancer 2000;88(11):2629-35.
2000: Christian Kollmannsberger; Craig Nichols; D D; Jörg Thomas Hartmann; Norbert Schleucher; Jörg Beyer; P Schöfski; Günter Derigs; U Rüther; I Böhlke; Hans-J Schmoll; Lothar Kanz; Carsten Bokemeyer
First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):553-9.
2000: Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma.
Anticancer research 2000;20(2B):1177-82.
2000: Jörg Thomas Hartmann; Craig Nichols; Jean Pierre Droz; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Karim Fizazi; Lawrence Einhorn; Lothar Kanz; Carsten Bokemeyer
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors.
Journal of the National Cancer Institute 2000;92(1):54-61.
2000: Carsten Bokemeyer; Christian Kollmannsberger; Jörg Thomas Hartmann; Lothar Kanz
Follow up after primary treatment: curable diseases treated non-surgically.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():73-8.
2000: Jörg Thomas Hartmann; Stefan Knop; Lüder M Fels; A van Vangerow; Hilmar Stolte; Lothar Kanz; Carsten Bokemeyer
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Anti-cancer drugs 2000;11(1):1-6.
1999: Jörg Thomas Hartmann; Christian Kollmannsberger; Lothar Kanz; Carsten Bokemeyer
Platinum organ toxicity and possible prevention in patients with testicular cancer.
International journal of cancer. Journal international du cancer 1999;83(6):866-9.
1999: Christian Kollmannsberger; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Therapy-related malignancies following treatment of germ cell cancer.
International journal of cancer. Journal international du cancer 1999;83(6):860-3.
1999: Carsten Bokemeyer; Christian Kollmannsberger; Andreas Harstrick; Jörg Beyer; Arthur Gerl; Jochen Casper; Bernd Metzner; Jörg Thomas Hartmann; Hans-J Schmoll; Lothar Kanz
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
International journal of cancer. Journal international du cancer 1999;83(6):848-51.
1999: Christian Kollmannsberger; M Kuzcyk; Frank Mayer; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Late toxicity following curative treatment of testicular cancer.
Seminars in surgical oncology 1999;17(4):275-81.
1999: Carsten Bokemeyer; Christian Kollmannsberger; Christoph Meisner; Andreas Harstrick; Jörg Beyer; Bernd Metzner; Jörg Thomas Hartmann; Hans-J Schmoll; Lawrence Einhorn; Lothar Kanz; Craig Nichols
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3450-6.
1999: Jörg Thomas Hartmann; Markus A Kuczyk; Christian Kollmannsberger; Lothar Kanz; Carsten Bokemeyer
Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
World journal of urology 1999;17(5):324-33.
1999: Jörg Thomas Hartmann; Detlef Quietzsch; Thomas Daikeler; Christian Kollmannsberger; Frank Mayer; Lothar Kanz; Carsten Bokemeyer
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Anti-cancer drugs 1999;10(8):729-33.
1999: Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Diagnosis and treatment of patients with testicular germ cell cancer.
Drugs 1999;58(2):257-81.
1999: Carsten Bokemeyer; Jörg Thomas Hartmann; Christian Kollmannsberger; Frank Mayer; Lothar Kanz
UFT/calcium folinate plus weekly paclitaxel for solid tumors.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):106-11.
1999: Christian Kollmannsberger; W Brugger; Jörg Thomas Hartmann; Franz Maurer; P Böhm; Lothar Kanz; Carsten Bokemeyer
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma.
Anti-cancer drugs 1999;10(5):453-6.
1999: Jörg Thomas Hartmann; C Albrecht; Hans-J Schmoll; Markus A Kuczyk; Christian Kollmannsberger; Carsten Bokemeyer
Long-term effects on sexual function and fertility after treatment of testicular cancer.
British journal of cancer 1999;80(5-6):801-7.
1999: Jörg Thomas Hartmann; Carsten Bokemeyer
Chemotherapy for renal cell carcinoma.
Anticancer research 1999;19(2C):1541-3.
1998: Christian Kollmannsberger; Jörg Beyer; Jean Pierre Droz; Andreas Harstrick; Jörg Thomas Hartmann; Pierre Biron; Aude Fléchon; Patrick Schöffski; Markus Kuczyk; Hans-J Schmoll; Lothar Kanz; Carsten Bokemeyer
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3386-91.
1998: Jörg Thomas Hartmann; Peter Albers; C Clemm; Rainer Souchon; Lothar Weissbach; D D; C Bokemeyer
[Register study for treatment of brain metastases of malignant testicular tumors].
Der Urologe. Ausg. A 1998;37(4):426-7.
1998: Jörg Thomas Hartmann; Claus-Henning Köhne; H J Schmoll; Thomas Daikeler; Lothar Kanz; Carsten Bokemeyer
Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
Oncology 1998;55(4):320-5.
1998: Jörg Thomas Hartmann; Andreas Harstrick; Thomas Daikeler; Christian Kollmannsberger; C Müller; S Seeber; Lothar Kanz; Carsten Bokemeyer
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Anti-cancer drugs 1998;9(5):427-31.
1998: Carsten Bokemeyer; C C Berger; Jörg Thomas Hartmann; Christian Kollmannsberger; Hans-J Schmoll; Markus A Kuczyk; Lothar Kanz
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
British journal of cancer 1998;77(8):1355-62.
1998: Carsten Bokemeyer; Jörg Thomas Hartmann; Markus A Kuczyk; M C Truss; Christian Kollmannsberger; Jörg Beyer; Udo Jonas; Lothar Kanz
Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
World journal of urology 1998;16(2):155-62.
1998: Jörg Thomas Hartmann; E Schmoll; Carsten Bokemeyer; R Fety; C Lucas; B Giroux; Hans-J Schmoll
Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases.
European journal of cancer (Oxford, England : 1990) 1998;34(1):87-91.
1998: Christian Kollmannsberger; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Journal of cancer research and clinical oncology 1998;124(3-4):207-14.
1997: Carsten Bokemeyer; Jörg Thomas Hartmann; C S Lampe; M R Clemens; Detlef Quietzsch; L Forkmann; Lothar Kanz
Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Seminars in oncology 1997;24(6 Suppl 19):S19-96-S19-100.
1997: Carsten Bokemeyer; A Franzke; Jörg Thomas Hartmann; C Schöber; L Arseniev; Bernd Metzner; H Link; Lothar Kanz; Hans-J Schmoll
A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Cancer 1997;80(7):1221-7.
1997: C Bokemeyer; Jörg Thomas Hartmann; L Kanz
[Current aspects of adjuvant and palliative chemotherapy in colorectal carcinoma].
Praxis 1997;86(39):1510-6.
1997: Thomas Daikeler; K Maas; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors.
Anti-cancer drugs 1997;8(6):643-4.
1997: Jörg Thomas Hartmann; Hans-J Schmoll; Markus A Kuczyk; M Candelaria; Carsten Bokemeyer
Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):531-8.
1997: Jörg Thomas Hartmann; M Candelaria; Markus A Kuczyk; Hans-J Schmoll; Carsten Bokemeyer
Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
European journal of cancer (Oxford, England : 1990) 1997;33(6):843-7.
1997: Carsten Bokemeyer; C S Lampe; M R Clemens; Jörg Thomas Hartmann; Detlef Quietzsch; L Forkmann; Christian Kollmannsberger; Lothar Kanz
A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer.
Anti-cancer drugs 1997;8(4):396-9.
1996: Carsten Bokemeyer; Jörg Thomas Hartmann; M A Kuczyk; Michael C Truss; Jörg Beyer; Udo Jonas; Lothar Kanz
The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
World journal of urology 1996;14(6):354-9.
1996: Carsten Bokemeyer; M A Kuczyk; Jürgen Serth; Jörg Thomas Hartmann; H J Schmoll; Udo Jonas; Lothar Kanz
Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.
Journal of cancer research and clinical oncology 1996;122(10):575-84.